|ASCO 2018 Annual Meeting Highlights in Multiple Myeloma|
CME, CPE, CNE
Sagar Lonial, MD, FACP; Robert Z. Orlowski, MD, PhD; Noopur Raje, MD; and Saad Z. Usmani, MD, FACP
|Release Date: July 25, 2018|
Expiration Date: July 25, 2019
In this activity, leading multiple myeloma investigators will present key highlights of several significant scientific updates in multiple myeloma presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. View video from the meeting and listen as they share their insights on a variety of abstracts, covering topics including, but not limited to: combination therapy with triplet and quadruplet regimens, immunotherapy, and safety and efficacy profiles of various treatment options in the upfront and relapsed/refractory settings.
This activity includes notable highlights in the ALCYONE (daratumumab), ELOQUENT-2 (elotuzumab), and OPTIMISMM (pomalidomide) trials among others, as well as developments in CAR T cell therapy in myeloma. Don’t miss this opportunity to see how the future of treatment in myeloma is continuing to evolve, and how these changes may positively impact patient outcomes.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
|Begin, Earn CreditView Only, No Credit|